Jupiter NeurosciencesJUNS +18.22%4 Gross Margin % is 73.68% as of Mar. 2026, which is 10% below its 10-year median of 81.82. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review. Among 735 Biotechnology companies, Jupiter Neurosciences ranks better than 80.27% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jupiter Neurosciences had a gross margin of 73.68% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jupiter Neurosciences Gross Margin % Related Terms
Jupiter Neurosciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Jupiter Neurosciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JUNS vs ZEOX, LEXX, GDTC: Gross Margin % Comparison
For the Biotechnology subindustry, Jupiter Neurosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jupiter Neurosciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jupiter Neurosciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jupiter Neurosciences (JUNS) has a Gross Margin % of 73.68% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jupiter Neurosciences and its competitors. This is 10% below median its historical median of 81.82. Over the past decade, Jupiter Neurosciences' Gross Margin % has ranged from 81.82 to 87.81. According to the industry distribution chart, Jupiter Neurosciences ranks #145 out of 735 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Jupiter Neurosciences' Gross Margin % too high?
Jupiter Neurosciences' current Gross Margin % of 73.68% is 10% below median its 10-year median of 81.82. Over the past 10 years, this metric has ranged from a low of 81.82 to a high of 87.81. The Biotechnology industry median Gross Margin % is 60.90. Jupiter Neurosciences' value of 73.68% is 21% above this industry median. Based on the distribution chart, Jupiter Neurosciences ranks #145 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' Gross Margin % compare to ZEOX and LEXX?
According to the Biotechnology industry distribution chart, Jupiter Neurosciences ranks #145 out of 735 companies for Gross Margin %. This places Jupiter Neurosciences in the top 20% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Jupiter Neurosciences' value of 73.68% is 21% above this benchmark. Historically, Jupiter Neurosciences' own Gross Margin % has ranged from 81.82 to 87.81 over the past decade. While the company's 10-year median is 81.82 vs. the industry median of 60.90, Jupiter Neurosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jupiter Neurosciences's current Gross Margin % of 73.68% is 21% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jupiter Neurosciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jupiter Neurosciences's current Gross Margin % is 73.68%, which is 10% below median its own 10-year median of 81.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Gross Margin % of 73.68%. The current Gross Margin % is 73.68%, which is 10% below median its 10-year median of 81.82 and 21% above the Biotechnology industry median of 60.90. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Gross Margin % is 73.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score
Get the complete analysis for JUNS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUNS has been successfully added to your 
